An event to launch three ground-breaking new collaborative partnerships set up by the charity Brain Tumour Research and three Research Centres of Excellence was held on the 4th March at the Speaker’s House, sponsored by QSRC.
Neil Kitchen (Medical Director), Lynne Brooks (Director) and Rebecca Robinson (Charities Co-ordinator) were amongst 150 guests attending with patients, carers, scientists, clinicians and charities from across the UK represented.
The partnerships open a new chapter in long-term sustainable and continuous research into the biggest cancer killer of children and adults under 40 and paves the way for a £20 million investment in brain tumour research over the next five years.
At the reception held at Speaker’s House John Bercow commented: “The news today that three new Centres of Excellence will be entering a funding partnership with Brain Tumour Research, thereby ensuring that research will be continuous and sustained, is really welcome to all those families, including mine, impacted by brain tumours. For so long, this disease has been the “Cinderella cancer”. This planned investment brings fresh hope that more effective treatments and ultimately a cure will be found… And soon.”
Building on their inaugural Centre at the University of Portsmouth, Brain Tumour Research’s collaboration with Queen Mary University of London working with UCL Institute of Neurology; Imperial College Healthcare NHS Trust (London); and Plymouth University Peninsula Schools of Medicine and Dentistry will create a network of flourishing brain tumour research centres throughout the UK where research work will include greater understanding of glioblastoma multiforme (GBM), low grade tumours and the biology of brain tumour metabolism.
With secure long-term funding covering the key salaried positions within these centres, the researchers will be freed from the limitations and frustrations of applying for one specific project grant after another and instead will be able to pursue the sustainable and continuous research so desperately needed by the scientists and clinicians working in this underfunded field.
Rebecca Robinson said “We at QSRC are very proud to support and collaborate with Brain Tumour Research and welcome this announcement. We have initiated a number of clinical research projects with the aim of providing robust evaluation on the clinical effectiveness of stereotactic radiosurgery using a Gamma Knife for the treatment of brain tumours and hope to improve access to this technology which offers significant benefits for patients”.
Further information can be found here.